Global Drug Delivery Market

Drug Delivery Market Size, Share, Growth Analysis, By Type(Oral Drug Delivery Systems, Injectable Drug Delivery Systems, Topical Drug Delivery Systems, Pulmonary Drug Delivery Systems), By Application(Oncology, Diabetes, Cardiovascular Diseases, Respiratory Diseases), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35C2017 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 67 | Figures: 75

Drug Delivery Market News

  • In December 2022, Johnson & Johnson announced the launch of its ACUITY™ MRI SureScan™ pacemaker. This pacemaker is the first and only MRI-conditional pacemaker that is also compatible with Johnson & Johnson's ACUITY™ MRI SureScan™ defibrillator.
  • In November 2022, Sorin Group announced the launch of its Evia™ leadless pacemaker. This pacemaker is a small, wireless device that is implanted directly into the heart without the need for leads.
  • In October 2022, Arena Pharmaceuticals announced the approval of its drug, ravulizumab, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Ravulizumab is a long-acting, subcutaneously administered C5 complement inhibitor that provides sustained protection from hemolysis in patients with PNH.
  • In September 2022, Alnylam Pharmaceuticals announced the approval of its drug, vutrisiran, for the treatment of hereditary transthyretin amyloidosis (ATTR amyloidosis). Vutrisiran is a subcutaneously administered RNA interference (RNAi) therapy that targets the production of TTR protein.
  • In August 2022, Sanofi announced the approval of its drug, Dupixent, for the treatment of atopic dermatitis in adults and children aged 6 years and older. Dupixent is a human monoclonal antibody that targets the IL-4 and IL-13 cytokines.
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.



Drug Delivery Market size was valued at USD 17.04 billion in 2021 and is poised to grow from USD 18.47 billion in 2022 to USD 35.21 billion by 2030, growing at a CAGR of 8.4% in the forecast period (2023-2030).

The drug delivery market is highly competitive and dynamic, characterised by the presence of numerous players operating across various segments and regions. This market encompasses a wide range of technologies and devices designed to deliver drugs efficiently and effectively to patients. The competitive landscape of the drug delivery market is shaped by factors such as technological advancements, product innovation, strategic collaborations, and regulatory compliance. 'Johnson & Johnson (US)', 'Pfizer Inc. (US)', 'Novartis International AG (Switzerland)', 'GlaxoSmithKline plc (United Kingdom)', 'Merck & Co., Inc. (US)', 'Sanofi (France)', 'AstraZeneca plc (United Kingdom)', 'Roche Holding AG (Switzerland)', 'Eli Lilly and Company (US)', 'Bayer AG (Germany)', 'Bristol-Myers Squibb Company (US)', 'AbbVie Inc. (US)', 'Amgen Inc. (US)', 'Novo Nordisk A/S (Denmark)', 'Gilead Sciences, Inc. (US)', 'Takeda Pharmaceutical Company Limited (Japan)', 'Biogen Inc. (US)', 'Astellas Pharma Inc. (Japan)', 'Boehringer Ingelheim International GmbH (Germany)', 'Daiichi Sankyo Company, Limited (Japan)'

The drug delivery market is witnessing an increasing trend towards self-administration of medications and home healthcare. Patients are increasingly seeking convenience and independence in managing their medications. User-friendly and portable drug delivery devices such as autoinjectors, inhalers, and insulin pens have emerged to meet this demand. These devices empower patients to administer medications at home, reducing the need for frequent hospital visits and enhancing overall convenience and patient satisfaction.

Increasing focus on targeted drug delivery systems: Targeted drug delivery involves delivering medications directly to specific sites in the body, allowing for localised treatment and minimising systemic side effects. This trend is driven by the need for more precise and effective drug therapies, especially in complex diseases such as cancer, autoimmune disorders, and chronic conditions. Targeted drug delivery systems utilise various technologies such as nanoparticles, liposomes, micelles, and implantable devices to deliver drugs to specific tissues, organs, or cells. These systems offer advantages such as enhanced drug efficacy, reduced dosage requirements, improved patient compliance, and minimise off-target effects.

North America has historically held a significant share in the pacemaker market, attributed to its well-developed healthcare infrastructure, high healthcare expenditure, and a large patient pool. The region has a strong presence of key market players, advanced technological advancements, and a high adoption rate of pacemaker technologies. Additionally, favourable reimbursement policies and increased awareness about cardiovascular diseases contribute to the dominance of North America in the pacemaker market.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.


Feedback From Our Clients

Global Drug Delivery Market

Report ID: SQMIG35C2017